Merck stock surges 11% following breakthrough Phase 3 cancer trial results with Moderna, while the company maintains a strong dividend profile and expands its AI capabilities through a new Google Cloud partnership.
Merck's positive Phase 3 cancer data, raised sales guidance, and dividend yield support a bullish outlook.
Positive Phase 3 data for personalized mRNA cancer therapy with Merck boosts Moderna's pipeline prospects.
Merck's multiyear deal with Google Cloud for AI tools could benefit Alphabet's cloud business.
Merck's outperformance relative to the Nasdaq Composite highlights the index's lower return.
Merck and Moderna reported successful Phase 3 results for their personalized mRNA cancer therapy, intismeran autogene, when used alongside Keytruda. The positive clinical data, combined with a raised 2026 sales forecast and a consistent dividend yield of 2.36%, has bolstered investor confidence despite recent one-time acquisition charges impacting short-term earnings.
Merck is investing up to $1 billion in a multiyear deal to integrate Google Cloud's AI tools, including Gemini Enterprise, to optimize research, manufacturing, and drug development processes for its 75,000 employees.
The loss was primarily driven by $5.7 billion in one-time charges related to the acquisition of Terns Pharmaceuticals, which significantly increased R&D expenditures.